ATM and infection: Our study also identified potent activity of ATM-AVI (MIC90 0.25–1 μg/mL) against ESBL-positive isolates across wards and infection sources, with ≥98.6% and ≥99.1% isolates, respectively, inhibited at ≤8 μg/mL globally and in all regions.